Epigallocatechin gallate induce cell death and apoptosis in triple negative breast cancer cells Hs578T

Journal of Drug Targeting

Volumn 21, Issue 3, 2013, Pages 250-256

  Braicu, Cornelia ^a   Gherman, Claudia ^b,c  

^a Cancer Institute Ion Chiricuta Cluj Napoca   (Romania)

^b Surgical Clinic No 2 Tg Mures   (Romania)

^c IULIU HATIEGANU UNIVERSITY OF MEDICINE AND PHARMACY   (Romania)

Author keywords

Apoptosis; Cell death; Epigallocatechin gallate; Hs578T cells

Indexed keywords

EPIGALLOCATECHIN GALLATE; MESSENGER RNA;

ANTIPROLIFERATIVE ACTIVITY; ARTICLE; CANCER CELL; CELL DEATH; CELL PROLIFERATION; CONTROLLED STUDY; DOWN REGULATION; DRUG EFFECT; GENE EXPRESSION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; TRIPLE NEGATIVE BREAST CANCER; UPREGULATION;

EID: 84875948793     PISSN: 1061186X     EISSN: 10292330     Source Type: Journal    
DOI: 10.3109/1061186X.2012.740673     Document Type: Article

References (51)

1. Arslan C, Dizdar O, Altundag K. (2009). Pharmacotherapy of triple-negative breast cancer. Expert Opin Pharmacother, 10, 2081-2093.
2. Bergamaschi D, Samuels Y, Jin B, Duraisingham S, Crook T, Lu X. (2004). ASPP1 and ASPP2: common activators of p53 family members. Mol Cell Biol, 24, 1341-1350.
3. Borska S, Gebarowska E, Wysocka T, Drag-Zalesinska M, Zabel M. (2003). Induction of apoptosis by EGCG in selected tumour cell lines in vitro. Folia Histochem Cytobiol, 41, 229-232.
4. Braicu C, Berindan-Neagoe I, Burz C, Balacescu O, Irimie A. (2009). Catechins therapeutic implications in cancer. Biol Ther Cancer Cell, 1(1), 81-84.
5. Braicu C, Rugina D, Chedea VS, Tudoran O, Balacescu O, Neagoe I, Socaciu C. (2010). Protective action of different natural flavan-3-ols against aflatoxin B1-related cytotoxicity. J Food Biochem, 4(3), 595-610.
6. Brenton JD, Carey LA, Ahmed AA, Caldas C. (2005). Molecular classification and molecular forecasting of breast cancer: ready for clinical application? J Clin Oncol, 23, 7350-7360.
7. Chedea VS, Braicu C, Socaciu C. (2010). Antioxidant/prooxidant activity of a polyphenolic grape seed extract. Food Chem, 121, 132-139.
8. Chisholm K, Bray BJ, Rosengren RJ. (2004). Tamoxifen and epigallocatechin gallate are synergistically cytotoxic to MDA-MB-231 human breast cancer cells. Anticancer Drugs, 15, 889-897.
9. Dai Y, Lawrence TS, Xu L. (2009). Overcoming cancer therapy resistance by targeting inhibitors of apoptosis proteins and nuclear factor-κB. Am J Transl Res, 1, 1-15.
10. Denoeud J, Moser M. (2011). Role of CD27/CD70 pathway of activation in immunity and tolerance. J Leukoc Biol, 89, 195-203.
11. Deveraux QL, Takahashi R, Salvesen GS, Reed JC. (1997). X-linked IAP is a direct inhibitor of cell-death proteases. Nature, 388, 300-304.
12. Dufner A, Pownall S, Mak TW. (2006). Caspase recruitment domain protein 6 is a microtubule-interacting protein that positively modulates NF-κB activation. Proc Natl Acad Sci USA, 103, 988-993.
13. Emery JG, McDonnell P, Burke MB, Deen KC, Lyn S, Silverman C, Dul E, Appelbaum ER, Eichman C, DiPrinzio R, Dodds RA, James IE, Rosenberg M, Lee JC, Young PR. (1998). Osteoprotegerin is a receptor for the cytotoxic ligand TRAIL. J Biol Chem, 273, 14363-14367.
14. Foulkes WD, Smith IE, Reis-Filho JS. (2010). Triple-negative breast cancer. N Engl J Med, 363, 1938-1948.
15. Guo S, Lu J, Subramanian A, Sonenshein GE. (2006). Microarray-assisted pathway analysis identifies mitogen-activated protein kinase signaling as a mediator of resistance to the green tea polyphenol epigallocatechin 3-gallate in her-2/neu-overexpressing breast cancer cells. Cancer Res, 66, 5322-5329.
16. Guo S, Liu M, Godwin AK. (2012). Transcriptional Regulation of hTREX84 in Human Cancer Cells. PLoS ONE, 7, e43610.
17. Huang DC, Strasser A. (2000). BH3-Only proteins-essential initiators of apoptotic cell death. Cell, 103, 839-842.
18. Huang J, Kerstann KW, Ahmadzadeh M, Li YF, El-Gamil M, Rosenberg SA, Robbins PF. (2006). Modulation by IL-2 of CD70 and CD27 expression on CD8+ T cells: importance for the therapeutic effectiveness of cell transfer immunotherapy. J Immunol, 176, 7726-7735.
19. Iwahana H, Yakymovych I, Dubrovska A, Hellman U, Souchelnytskyi S. (2006). Glycoproteome profiling of transforming growth factor-β (TGFβ) signaling: nonglycosylated cell death-inducing DFF-like effector A inhibits TGFβ1-dependent apoptosis. Proteomics, 6, 6168-6180.
20. Kang JS, Bae SY, Kim HR, Kim YS, Kim DJ, Cho BJ, Yang HK, Hwang YI, Kim KJ, Park HS, Hwang DH, Cho DJ, Lee WJ. (2009). Interleukin-18 increases metastasis and immune escape of stomach cancer via the downregulation of CD70 and maintenance of CD44. Carcinogenesis, 30, 1987-1996.
21. Kim J, Zhang X, Rieger-Christ KM, Summerhayes IC, Wazer DE, Paulson KE, Yee AS. (2006). Suppression of Wnt signaling by the green tea compound (-)-epigallocatechin 3-gallate (EGCG) in invasive breast cancer cells. Requirement of the transcriptional repressor HBP1. J Biol Chem, 281, 10865-10875.
22. Kim S, Choi MG, Lee HS, Lee SK, Kim SH, Kim WW, Hur SM, Kim JH, Choe JH, Nam SJ, Yang JH, Kim S, Lee JE, Kim JS. (2009). Silibinin suppresses TNF-α-induced MMP-9 expression in gastric cancer cells through inhibition of the MAPK pathway. Molecules, 14, 4300-4311.
23. Koh KK, Bui MN, Mincemoyer R, Cannon RO 3rd. (1997). Effects of hormone therapy on inflammatory cell adhesion molecules in postmenopausal healthy women. Am J Cardiol, 80, 1505-1507.
24. Kutuk O, Letai A. (2008). Alteration of the mitochondrial apoptotic pathway is key to acquired paclitaxel resistance and can be reversed by ABT-737. Cancer Res, 68, 7985-7994.
25. Letai A, Bassik MC, Walensky LD, Sorcinelli MD, Weiler S, Korsmeyer SJ. (2002). Distinct BH3 domains either sensitize or activate mitochondrial apoptosis, serving as prototype cancer therapeutics. Cancer Cell, 2, 183-192.
26. Mitchell C, Yacoub A, Hossein H, Martin AP, Bareford MD, Eulitt P, Yang C, Nephew KP, Dent P. (2010). Inhibition of MCL-1 in breast cancer cells promotes cell death in vitro and in vivo. Cancer Biol Ther, 10, 903-917.
27. Neve RM, Chin K, Fridlyand J, Yeh J, Baehner FL, Fevr T, Clark L, Bayani N, Coppe JP, Tong F, Speed T, Spellman PT, DeVries S, Lapuk A, Wang NJ, Kuo WL, Stilwell JL, Pinkel D, Albertson DG, Waldman FM, McCormick F, Dickson RB, Johnson MD, Lippman M, Ethier S, Gazdar A, Gray JW. (2006). A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes. Cancer Cell, 10, 515-527.
28. Pan MH, Lin CC, Lin JK, Chen WJ. (2007). Tea polyphenol (-)-epigallocatechin 3-gallate suppresses heregulin-β1-induced fatty acid synthase expression in human breast cancer cells by inhibiting phosphatidylinositol 3-kinase/Akt and mitogenactivated protein kinase cascade signaling. J Agric Food Chem, 55, 5030-5037.
29. Pianetti S, Guo S, Kavanagh KT, Sonenshein GE. (2002). Green tea polyphenol epigallocatechin-3 gallate inhibits Her-2/neu signaling, proliferation, and transformed phenotype of breast cancer cells. Cancer Res, 62, 652-655.
30. Puig T, Vázquez-Martín A, Relat J, Pétriz J, Menéndez JA, Porta R, Casals G, Marrero PF, Haro D, Brunet J, Colomer R. (2008). Fatty acid metabolism in breast cancer cells: differential inhibitory effects of epigallocatechin gallate (EGCG) and C75. Breast Cancer Res Treat, 109, 471-479.
31. Rahman M, Davis SR, Pumphrey JG, Bao J, Nau MM, Meltzer PS, Lipkowitz S. (2009). TRAIL induces apoptosis in triple-negative breast cancer cells with a mesenchymal phenotype. Breast Cancer Res Treat, 113, 217-230.
32. Reis-Filho JS, Tutt AN. (2008). Triple negative tumours: a critical review. Histopathology, 52, 108-118.
33. Rivas MA, Carnevale RP, Proietti CJ, Rosemblit C, Beguelin W, Salatino M, Charreau EH, Frahm I, Sapia S, Brouckaert P, Elizalde PV, Schillaci R. (2008). TNF α acting on TNFR1 promotes breast cancer growth via p42/P44 MAPK, JNK, Akt and NF-κB-dependent pathways. Exp Cell Res, 314, 509-529.
34. Rochester MA, Riedemann J, Hellawell GO, Brewster SF, Macaulay VM. (2005). Silencing of the IGF1R gene enhances sensitivity to DNAdamaging agents in both PTEN wild-type and mutant human prostate cancer. Cancer Gene Ther, 12, 90-100.
35. Roy A, Baliga M, Katiyar S. (2005). Epigallocatechin-3-gallate induces apoptosis in estrogen receptor-negative human breast carcinoma cells via modulation in protein expression of p53 and Bax and caspase-3 activation. Mol Can Therap, 1(4), 1535-7163.
36. Scandlyn MJ, Stuart EC, Somers-Edgar TJ, Menzies AR, Rosengren RJ. (2008). A new role for tamoxifen in oestrogen receptor-negative breast cancer when it is combined with epigallocatechin gallate. Br J Cancer, 99, 1056-1063.
37. Shankar S, Ganapathy S, Hingorani SR, Srivastava RK. (2008). EGCG inhibits growth, invasion, angiogenesis and metastasis of pancreatic cancer. Front Biosci, 13, 440-452.
38. Singh BN, Shankar S, Srivastava RK. (2011). Green tea catechin, epigallocatechin-3-gallate (EGCG): mechanisms, perspectives and clinical applications. Biochem Pharmacol, 82, 1807-1821.
39. Stuart E, Larsen L. (2007). Rosengren R. Potential mechanisms for the synergistic cytotoxicity elicited by 4-hydroxytamoxifen and epigallocatechin gallate in MDAMB-231 cells. Int J Oncol, 6(30), 1019-6439.
40. Stuart EC, Scandlyn MJ, Rosengren RJ. (2006). Role of epigallocatechin gallate (EGCG) in the treatment of breast and prostate cancer. Life Sci, 79, 2329-2336.
41. Tang SN, Singh C, Nall D, Meeker D, Shankar S, Srivastava RK. (2010). The dietary bioflavonoid quercetin synergizes with epigallocathechin gallate (EGCG) to inhibit prostate cancer stem cell characteristics, invasion, migration and epithelial-mesenchymal transition. J Mol Signal, 5, 14.
42. Tang Y, Zhao DY, Elliott S, Zhao W, Curiel TJ, Beckman BS, Burow ME. (2007). Epigallocatechin-3 gallate induces growth inhibition and apoptosis in human breast cancer cells through survivin suppression. Int J Oncol, 31, 705-711.
43. Thangapazham RL, Passi N, Maheshwari RK. (2007). Green tea polyphenol and epigallocatechin gallate induce apoptosis and inhibit invasion in human breast cancer cells. Cancer Biol Ther, 6, 1938-1943.
44. Thangapazham RL, Singh AK, Sharma A, Warren J, Gaddipati JP, Maheshwari RK. (2007). Green tea polyphenols and its constituent epigallocatechin gallate inhibits proliferation of human breast cancer cells in vitro and in vivo. Cancer Lett, 245, 232-241.
45. Vosjan MJ, Vercammen J, Kolkman JA, Stigter-van Walsum M, Revets H, van Dongen GA. (2012). Nanobodies targeting the hepatocyte growth factor: potential new drugs for molecular cancer therapy. Mol Cancer Ther, 11, 1017-1025.
46. Walter-Yohrling J, Cao X, Callahan M, Weber W, Morgenbesser S, Madden SL, Wang C, Teicher BA. (2003). Identification of genes expressed in malignant cells that promote invasion. Cancer Res, 63, 8939-8947.
47. Wang Z, Fukushima H, Inuzuka H, Wan L, Liu P, Gao D, Sarkar FH, Wei W. (2012). Skp2 is a promising therapeutic target in breast cancer. Front Oncol, 1, 18702.
48. Yang CS, Wang H. (2011). Mechanistic issues concerning cancer prevention by tea catechins. Mol Nutr Food Res, 55(6), 819-831.
49. Yang JP, Ono T, Sonta S, Kawabe T, Okamoto T. (1997). Assignment of p53 binding protein (TP53BP2) to human chromosome band 1q42.1 by in situ hybridization. Cytogenet Cell Genet, 78(1), 61-62.
50. Yonezawa T, Kurata R, Kimura M, Inoko H. (2011). Which CIDE are you on? Apoptosis and energy metabolism. Mol Biosyst, 7(1), 91-100.
51. Zhu H, Liu P, Li J. (2012). BAG3: a new therapeutic target of human cancers? http://www.um.es/hh/Reviews-proofs/Zhu%20et%20al.pdf